Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Study of GC1118 in Combination With Irinotecan or FOLFIRI in Patients With Recurrent/Metastatic Solid Tumor

NCT03454620 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT03454620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03454620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Study of GC1118 in Combination With Irinotecan or FOLFIRI in Patients With Recurrent/Metastatic Solid Tumor
Lead sponsor
Green Cross Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
April 2, 2018
Completion date
January 10, 2022
Enrollment
53 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer, solid tumor